Biodexa Pharmaceuticals (BDRX) Registration Filing summary

Financial performance and metrics

• Reported a net loss of £3.31 million for the six months ended June 30, 2024, and £7.08 million for the year ended December 31, 2023, with an accumulated deficit of £147.88 million as of June 30, 2024.

• Cash and cash equivalents were £5.06 million as of June 30, 2024, expected to fund operations into Q1 2025; additional financing is required to continue as a going concern.

• Revenue for the six months ended June 30, 2024, was nil, compared to £0.30 million in the prior year period; 2023 full-year revenue was £0.38 million, down from £0.70 million in 2022.

• Research and development costs for the six months ended June 30, 2024, were £2.19 million, and administrative costs were £2.03 million; both categories saw reductions compared to the prior year.

• The audit opinion includes a going concern uncertainty due to recurring losses and the need for additional funding before Q1 2025.

Company overview and business model

• Focuses on developing clinical-stage assets for diseases with unmet medical needs, including FAP, NMIBC, T1D, and rare/orphan brain cancers.

• Recent strategic shift to prioritize therapeutics over drug delivery technologies, with a business model centered on advancing assets to proof-of-concept before partnering for late-stage development and commercialization.

• Pipeline includes eRapa (licensed in April 2024), tolimidone (licensed December 2023), and MTX110, all in various stages of clinical development.

Use of proceeds and capital allocation

• May receive up to $35 million in gross proceeds from the equity line with C/M Capital Master Fund, LP, to be used for development programs, working capital, and general corporate purposes.

• Proceeds are expected to be invested in short-term, interest-bearing investments pending use.

• No proceeds will be received from the resale of shares by the selling shareholder.